Search

Displaying results 131 - 140 of 4018 in total
  1. Target

    Disulfide bond formation protein B

    go.drugbank.com/bio_entities/BE0004378
    TargetEscherichia coli (strain K12)

    Required for disulfide bond formation in some periplasmic proteins such as PhoA or OmpA. Acts by oxidizing the DsbA protein.

    Polypeptides: Disulfide bond formation protein B
  2. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.

  3. Drug

    Gentamicin

    go.drugbank.com/drugs/DB00798
    ApprovedInvestigationalVet approved

    Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. G...

    Products: REFOBACIN BONE CEMENT R
  4. Drug

    Calcium

    go.drugbank.com/drugs/DB01373
    ApprovedInvestigationalNutraceutical

    Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium.

    Mixtures: BION 3 FILM COATED TABLETCategories: Drugs for Treatment of Bone Diseases, Drugs Affecting Bone Structure and Mineralization
  5. Indication

    High risk, refractory Neuroblastomas of the bone or bone marrow

    go.drugbank.com/conditions/DBCOND0134732
    Drugs: Naxitamab
    Synonyms: High risk, refractory Neuroblastomas of the bone or bone marrow
  6. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

  7. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  8. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    ApprovedInvestigational

    Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

  9. Target

    F-box only protein 41

    go.drugbank.com/bio_entities/BE0009024
    TargetHumans

    Substrate-recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex. Required in the developing brain for neuronal migration and long-term cerebellar integrity.

    Polypeptides: F-box only protein 41
  10. Target

    T-box transcription factor T

    go.drugbank.com/bio_entities/BE0011656
    TargetHumans

    Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence and activates gene transcription when bound to such a site

    Polypeptides: T-box transcription factor T